Table 1 Demographic and clinical characteristics Round 1(n = 100) and Round 2 (n = 10)
Participant characteristics | Round 1 n = 100 | Round 2 n = 10a |
|---|---|---|
Age | ||
Mean (SD) | 59.3 years (±12.1) | 63,4 (±8.5) |
Range in years | 28–85 | 51–80 |
% > 65 years of age | 34% | 30% |
Sex n (%) | ||
Female | 51 (51) | 4 (40) |
Male | 57 (57) | 6 (60) |
Education | ||
Mean years (SD) | 14.4 (2.3) | 12.0 (1,6) |
% lower than high school: (or nearest equivalent) | 7 | 20 |
% high school or higher: (or nearest equivalent) | 93 | 50 |
Missing (%) | 0 | 30 |
Type of treatment n (%)b | ||
Combined Chemo-radiotherapy | 36 (36) | 5 (50) |
Chemotherapy | 26 (26) | 5 (50) |
Radiotherapy | 39 (39) | 2 (20) |
Hormonal therapy | 13 (13) | 1 (10) |
Part of clinical trial | 5 (5) | 0 (0) |
Immune therapy | 10 (10) | 0 (0) |
Molecularly targeted therapy | 8 (8) | 1 (10) |
Cancer site n (%) | ||
Breast | 24 (24) | 2 (20) |
Hematological | 22 (22) | 3 (30) |
Urological | 14 (14) | 2 (20) |
Lung | 13 (13) | 0 (0) |
Gynecological | 11 (11) | 2 (20) |
Head and neck | 10 (10) | 1 (10) |
Gastrointestinal | 8 (8) | 0 (0) |
Brain | 4 (4) | 0 (0) |
Skin | 2 (2) | 0 (0) |
Performance statusc | ||
Karnofsky Performance Scale Index | ||
90–100 | 17 (17) | 2 (20) |
60–89 | 20 (20) | 3 (30) |
< 60 | 3 (3) | 0 (0) |
Missing % | 60 (60) | 5 (50) |
Country n (%) | ||
The Netherlands | 60 (60) | 5 (50) |
Dutch-speaking Belgium | 40 (40) | 5 (50) |